
Mice Model
Description
Global Mice Model Market to Reach US$2.6 Billion by 2030
The global market for Mice Model estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. CRISPR / CAS9, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$976.7 Million by the end of the analysis period. Growth in the Microinjection segment is estimated at 4.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$508.8 Million While China is Forecast to Grow at 8.1% CAGR
The Mice Model market in the U.S. is estimated at US$508.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$603.1 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.
Global Mice Model Market - Key Trends & Drivers Summarized
What Are Mice Models, and Why Are They Crucial in Biomedical Research?
Mice models are laboratory mice used by scientists to study human diseases, genetics, and drug responses. These models are essential for biomedical research because mice share many physiological and genetic similarities with humans, making them excellent subjects for studying a wide range of human conditions, including cancer, heart disease, diabetes, and neurological disorders. The ability to manipulate the mouse genome and create genetically modified mice has significantly enhanced the value of these models in research, allowing for targeted studies on specific genes or disease processes. This capability makes mice models indispensable tools for understanding disease mechanisms, identifying potential therapeutic targets, and evaluating new drugs and treatments.
How Are Genetic Modifications Advancing Mice Model Research?
Genetic modifications in mice models have revolutionized biomedical research, allowing for more precise and targeted studies. Techniques such as CRISPR/Cas9 gene editing have made it possible to create mice with specific genes knocked out or modified, which can mimic human genetic conditions or diseases closely. These advancements have not only accelerated the pace of research but also improved the relevance of mice models to human health. As these techniques become more refined, they enhance the ability to model complex human diseases in mice, leading to more effective drugs, faster development timelines, and ultimately, better patient outcomes.
What Challenges Do Researchers Face With Mice Models?
Despite their extensive use, researchers face challenges with mice models, particularly concerning the accuracy with which these models replicate human diseases. Differences in mouse and human immune systems, metabolism, and biology can lead to discrepancies in how diseases manifest and respond to treatments in mice versus humans. Additionally, the high costs associated with developing, maintaining, and housing genetically engineered mice can be prohibitive, especially in high-throughput studies or in institutions with limited funding. Ethical considerations also play a significant role, as the welfare of animals in research must be meticulously managed to adhere to ethical standards and regulatory guidelines.
What Drives the Growth in the Mice Model Market?
The growth in the mice model market is driven by several factors, including the ongoing need for effective models in the rapidly expanding fields of genetics and personalized medicine. Innovations in genetic engineering and genome editing technologies have broadened the applications of mice models in research, making them more valuable for studying complex genetic interactions and diseases. The rise in chronic diseases globally and the push for more personalized, targeted therapies have also spurred demand for specialized mice models. Furthermore, the increasing investment in pharmaceutical R&D, coupled with growing collaborations between academic institutions and biotechnology companies, supports the continuous development and refinement of mice models. As the biomedical landscape evolves with new scientific advancements and regulatory requirements, the reliance on mice models is expected to remain strong, driving further innovations and expansions in this vital market.
The report analyzes the Mice Model market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Technology (CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer, Other Technologies); Service (Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing, Other Services); Therapeutic Area (Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular, Other Therapeutic Areas)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 46 Featured) -
- Charles River Laboratories International, Inc.
- Envigo, Inc.
- Genoway S.A.
- Harbour Antibodies BV
- Horizon Discovery Group PLC
- inGenious Targeting Laboratory, Inc.
- Janvier Labs
- Laboratory Corporation of America Holdings (LabCorp)
- Taconic Biosciences, Inc.
- The Jackson Laboratory
- Trans Genic, Inc.
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Mice Model – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Biomedical Research Advances Drive Demand for Genetically Modified Mice Models
- Rising Prevalence of Chronic Diseases Amplifies Need for Effective Mice Models
- Technological Innovations in Gene Editing Propel Development of Specialized Mice Models
- Pharmaceutical Industry Focus on Personalized Medicine Boosts Use of Mice Models
- Advancements in Cancer Research Reliance on Mice Models for Drug Development
- Ethical and Regulatory Developments Impact Mice Model Use and Care
- Expansion of Contract Research Organizations (CROs) Increases Availability of Mice Models
- Educational Institutions Research Needs Support Growth in Mice Model Market
- Development of Disease-Resistant Mice Models Opens New Research Avenues
- 3D Printing and Synthetic Biology Impact Mice Model Development
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Mice Model Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for CRISPR / CAS9 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Microinjection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Embryonic Stem Cell Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Nuclear Transfer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Breeding by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Cryopreservation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 29: World Recent Past, Current & Future Analysis for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 30: World Historic Review for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 31: World 15-Year Perspective for Quarantine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 32: World Recent Past, Current & Future Analysis for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 33: World Historic Review for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 34: World 15-Year Perspective for Model-In Licensing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 35: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 36: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 37: World 15-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 38: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 39: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 40: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 41: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 42: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 43: World 15-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 44: World Recent Past, Current & Future Analysis for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 45: World Historic Review for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 46: World 15-Year Perspective for Immunology & Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 47: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 48: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 49: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 50: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 51: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 52: World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 53: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 54: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 55: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 56: USA Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: USA Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 58: USA 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 59: USA Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 60: USA Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 61: USA 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 62: USA Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: USA Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 64: USA 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- CANADA
- TABLE 65: Canada Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 66: Canada Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 67: Canada 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 68: Canada Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 69: Canada Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 70: Canada 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 71: Canada Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 72: Canada Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 73: Canada 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- JAPAN
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 74: Japan Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 75: Japan Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 76: Japan 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 77: Japan Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 78: Japan Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 79: Japan 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 80: Japan Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 81: Japan Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 82: Japan 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- CHINA
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 83: China Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 84: China Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 85: China 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 86: China Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 87: China Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 88: China 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 89: China Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 90: China Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 91: China 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- EUROPE
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 92: Europe Recent Past, Current & Future Analysis for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 93: Europe Historic Review for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 94: Europe 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 95: Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 96: Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 97: Europe 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 98: Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 99: Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 100: Europe 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 101: Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 102: Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 103: Europe 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- FRANCE
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 104: France Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 105: France Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 106: France 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 107: France Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 108: France Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 109: France 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 110: France Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 111: France Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 112: France 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- GERMANY
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 113: Germany Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 114: Germany Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 115: Germany 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 116: Germany Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 117: Germany Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 118: Germany 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 119: Germany Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 120: Germany Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 121: Germany 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- ITALY
- TABLE 122: Italy Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 123: Italy Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 124: Italy 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 125: Italy Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 126: Italy Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 127: Italy 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 128: Italy Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 129: Italy Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 130: Italy 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 131: UK Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 132: UK Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 133: UK 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 134: UK Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 135: UK Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 136: UK 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 137: UK Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 138: UK Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 139: UK 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 140: Spain Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 141: Spain Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 142: Spain 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 143: Spain Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 144: Spain Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 145: Spain 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 146: Spain Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 147: Spain Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 148: Spain 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 149: Russia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 150: Russia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 151: Russia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 152: Russia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 153: Russia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 154: Russia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 155: Russia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 156: Russia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 157: Russia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 159: Rest of Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 160: Rest of Europe 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 162: Rest of Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 163: Rest of Europe 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 165: Rest of Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 166: Rest of Europe 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 168: Asia-Pacific Historic Review for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 169: Asia-Pacific 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 171: Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 172: Asia-Pacific 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 174: Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 175: Asia-Pacific 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 177: Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 178: Asia-Pacific 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- AUSTRALIA
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 179: Australia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 180: Australia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 181: Australia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 182: Australia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 183: Australia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 184: Australia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 185: Australia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 186: Australia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 187: Australia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- INDIA
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 188: India Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 189: India Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 190: India 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 191: India Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 192: India Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 193: India 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 194: India Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 195: India Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 196: India 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 197: South Korea Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 198: South Korea Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 199: South Korea 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 200: South Korea Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 201: South Korea Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 202: South Korea 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 203: South Korea Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 204: South Korea Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 205: South Korea 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 207: Rest of Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 210: Rest of Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 213: Rest of Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 215: Latin America Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 216: Latin America Historic Review for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 217: Latin America 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 218: Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 219: Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 220: Latin America 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 221: Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 222: Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 223: Latin America 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 224: Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 225: Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 226: Latin America 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 227: Argentina Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 228: Argentina Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 229: Argentina 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 230: Argentina Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 231: Argentina Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 232: Argentina 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 233: Argentina Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 234: Argentina Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 235: Argentina 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 236: Brazil Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 237: Brazil Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 238: Brazil 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 239: Brazil Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 240: Brazil Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 241: Brazil 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 242: Brazil Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 243: Brazil Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 244: Brazil 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 245: Mexico Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 246: Mexico Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 247: Mexico 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 248: Mexico Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 249: Mexico Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 250: Mexico 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 251: Mexico Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 252: Mexico Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 253: Mexico 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 255: Rest of Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 256: Rest of Latin America 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 258: Rest of Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 259: Rest of Latin America 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 261: Rest of Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 262: Rest of Latin America 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 263: Middle East Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 264: Middle East Historic Review for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 265: Middle East 15-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 266: Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 267: Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 268: Middle East 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 269: Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 270: Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 271: Middle East 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 272: Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 273: Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 274: Middle East 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- IRAN
- TABLE 275: Iran Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 276: Iran Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 277: Iran 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 278: Iran Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 279: Iran Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 280: Iran 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 281: Iran Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 282: Iran Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 283: Iran 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 284: Israel Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 285: Israel Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 286: Israel 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 287: Israel Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 288: Israel Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 289: Israel 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 290: Israel Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 291: Israel Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 292: Israel 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 294: Saudi Arabia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 295: Saudi Arabia 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 297: Saudi Arabia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 298: Saudi Arabia 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 300: Saudi Arabia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 301: Saudi Arabia 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 302: UAE Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 303: UAE Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 304: UAE 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 305: UAE Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 306: UAE Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 307: UAE 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 308: UAE Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 309: UAE Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 310: UAE 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 312: Rest of Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 313: Rest of Middle East 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 315: Rest of Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 316: Rest of Middle East 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 318: Rest of Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 319: Rest of Middle East 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- AFRICA
- Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 320: Africa Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 321: Africa Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 322: Africa 15-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2015, 2025 & 2030
- TABLE 323: Africa Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 324: Africa Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 325: Africa 15-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2015, 2025 & 2030
- TABLE 326: Africa Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 327: Africa Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 328: Africa 15-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates